An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2017
At a glance
- Drugs E 7046 (Primary)
- Indications Rectal cancer
- Focus Adverse reactions
- Acronyms PRAER 1
- Sponsors Eisai Co Ltd
- 14 Aug 2017 Planned End Date changed from 1 Nov 2019 to 1 Jan 2019.
- 14 Aug 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Apr 2018.
- 14 Aug 2017 Status changed from not yet recruiting to recruiting.